Joseph Maroon - Mylan N Insider

MYL -- USA Stock  

USD 30.55  0.25  0.83%

Dr. Joseph C. Maroon, M.D., is an Independent Director of Mylan Inc., since 2003. Dr. Maroon is currently Professor, Heindl Scholar in Neuroscience and Vice Chairman of the Department of Neurosurgery, University of Pittsburgh Medical Center, and has held other positions at UPMC since 1998. He has also served as the team neurosurgeon for the Pittsburgh Steelers since 1981. From 1995 to 1998, Dr. Maroon was Professor and Chairman of the Department of Surgery at Allegheny General Hospital, and from 1984 to 1999 he was Professor and Chairman of the Department of Neurosurgery at Allegheny General Hospital. Dr. Maroon has earned numerous awards for his contributions to neurosurgery from various national and international neurological societies throughout his career, and patients travel from all over the world to seek his care.
Age: 73  Director Since 2003      

Joseph Maroon Latest Insider Activity

Management Efficiency

The company has Return on Asset of 3.44 % which means that on every $100 spent on asset it made $3.44 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 4.3 % implying that it generated $4.3 on every 100 dollars invested.
The company has 14.44B in debt with debt to equity (D/E) ratio of 119.6 . This implies that the company may be unable to create cash to meet all of its financial commitments. Mylan N V has Current Ratio of 1.23 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Gary SollisESSA Pharma
Michael HarringtonElanco Animal Health
Sander FlaumEagle Pharmaceuticals
Lawrence KurziusElanco Animal Health
Kapila AnandElanco Animal Health
Aarti ShahElanco Animal Health
Kenneth KlepperDiplomat Pharmacy
Michael HyattEndo International plc
Ann MerrifieldFlexion Therapeutics
Edward KayEagle Pharmaceuticals
Marcus SmithFibrocell Science
Jeffrey ParkDiplomat Pharmacy
Kelvin MooreFibrocell Science
David PernockEagle Pharmaceuticals
Kenneth WidderEvoke Pharma
Arthur HigginsEndo International plc
Shane CookeEndo International plc
William MontagueEndo International plc
David HoffmannDURECT Corporation
Benjamin WolinDiplomat Pharmacy
Jill SmithEndo International plc

Entity Summary

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Mylan N operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 35000 people.Mylan N V (MYL) is traded on BATS Exchange in USA. It is located in United Kingdom and employs 35,000 people. Mylan N is listed under Pharmaceutical Products category by Fama And French industry classification.

Mylan N V Leadership Team

Anthony Mauro, President of Mylan North America
Joseph Maroon, Independent Director
Kris King, VP of Global Investor Relations
Heather Bresch, CEO, Executive Director and Member of Science and Technology Committee
Melina Higgins, Independent Director
Mark Parrish, Independent Director
Kenneth Parks, CFO
Rodney Piatt, Vice Chairman of the Board, Lead Independent Director
Rajiv Malik, President, Executive Director and Member of Science and Technology Committee
John Sheehan, Executive Vice President CFO, Principal Financial officer
Dennis Zeleny, Chief Human Resource Officer
JoEllen Dillon, Independent Director
Neil Dimick, Independent Director
Sjoerd Vollebregt, Independent Director
Douglas Leech, Independent Director
Robert Cindrich, Independent Director
Wendy Cameron, Independent Director
Rakesh Bamzai, President - India Commercial and Emerging Markets
Robert Coury, Executive Chairman and Chairman of Executive Committee
Daniel Gallagher, Chief Legal Officer
Randall Vanderveen, Independent Director

Stock Performance Indicators

Did you try this?

Run Positions Ratings Now


Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Positions Ratings

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..